Review Article| Volume 41, ISSUE 1, P153-171, March 2021

Novel Blood Component Therapies in the Pediatric Setting

  • Shannon C. Walker
    Department of Pediatrics, Division of Hematology/Oncology, Vanderbilt University Medical Center, Preston Research Building #397, 2220 Pierce Avenue, Nashville, TN 37232, USA
    Search for articles by this author
  • Jennifer Andrews
    Corresponding author. Vanderbilt University Medical Center, 1301 Medical Center Drive, Suite 4605, Nashville, TN 37232, USA.
    Department of Pathology, Microbiology and Immunology, Division of Transfusion Medicine, Vanderbilt University Medical Center, 1301 Medical Center Drive, Suite 4605, Nashville, TN 37232, USA

    Department of Pediatrics, Division of Hematology/Oncology, Vanderbilt University Medical Center, 1301 Medical Center Drive, Suite 4605, Nashville, TN 37232, USA
    Search for articles by this author
Published:December 14, 2020DOI:


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.


      Subscribe to Clinics in Laboratory Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Spinella P.C.
        • Cap A.P.
        Whole blood: back to the future.
        Curr Opin Hematol. 2016; 23: 536-542
        • Manno C.S.
        • Hedberg K.W.
        • Kim H.C.
        • et al.
        Comparison of the hemostatic effects of fresh whole blood, stored whole blood, and components after open heart surgery in children.
        Blood. 1991; 77: 930-936
        • Leeper C.M.
        • Yazer M.H.
        • Cladis F.P.
        • et al.
        Use of uncrossmatched cold-stored whole blood in injured children with hemorrhagic shock.
        JAMA Pediatr. 2018; 172: 491-492
        • Leeper C.M.
        • Yazer M.H.
        • Cladis F.P.
        • et al.
        Cold-stored whole blood platelet function is preserved in injured children with hemorrhagic shock.
        J Trauma Acute Care Surg. 2019; 87: 49-53
        • Thottathil P.
        • Sesok-Pizzini D.
        • Taylor J.A.
        • et al.
        Whole blood in pediatric craniofacial reconstruction surgery.
        J Craniofac Surg. 2017; 28: 1175-1178
        • Groom R.C.
        • Froebe S.
        • Martin J.
        • et al.
        Update on pediatric perfusion practice in North America: 2005 survey.
        J Extra Corpor Technol. 2005; 37: 343-350
        • Mou S.S.
        • Giroir B.P.
        • Molitor-Kirsch E.A.
        • et al.
        Fresh whole blood versus reconstituted blood for pump priming in heart surgery in infants.
        N Engl J Med. 2004; 351: 1635-1644
        • Valleley M.S.
        • Buckley K.W.
        • Hayes K.M.
        • et al.
        Are there benefits to a fresh whole blood vs. packed red blood cell cardiopulmonary bypass prime on outcomes in neonatal and pediatric cardiac surgery?.
        J Extra Corpor Technol. 2007; 39: 168-176
        • Gruenwald C.E.
        • McCrindle B.W.
        • Crawford-Lean L.
        • et al.
        Reconstituted fresh whole blood improves clinical outcomes compared with stored component blood therapy for neonates undergoing cardiopulmonary bypass for cardiac surgery: a randomized controlled trial.
        J Thorac Cardiovasc Surg. 2008; 136: 1442-1449
        • Jobes D.R.
        • Sesok-Pizzini D.
        • Friedman D.
        Reduced transfusion requirement with use of fresh whole blood in pediatric cardiac surgical procedures.
        Ann Thorac Surg. 2015; 99: 1706-1711
        • Stramer S.L.
        • Galel S.A.
        Infectious disease screening.
        in: Fung M.K. Eder A.F. Spitaknik S.L. Technical Manual. 19th ed. American Association of Blood Banks, Bethesda, MD2017: 161-205
        • Jacquot C.
        • Delaney M.
        Pathogen-inactivated blood products for pediatric patients: blood safety, patient safety, or both?.
        Transfusion. 2018; 58: 2095-2101
      1. “Octaplas pediatric approval”. US Food and Drug administration.
        (Available at:) (Accessed August 27, 2020)
      2. Octaplas [package insert]. Octapharma, Hoboken (NJ)2019
        • Camazine M.N.
        • Karam O.
        • Colvin R.
        • et al.
        Outcomes related to the use of frozen plasma or pooled solvent/detergent-treated plasma in critically ill children.
        Pediatr Crit Care Med. 2017; 18: e215-e223
      3. Intercept blood system platelet [package insert]. Cerus Corporation, Concord (CA)2019
        • Lu W.
        • Fung M.
        Platelets treated with pathogen reduction technology: current status and future direction.
        F1000Res. 2020; 9: F1000
        • Cerus Corporation
        An open label, post-marketing surveillance study following transfusion of INTERCEPT platelet components (PIPER). (Identifier NCT02549222).
        (Available at:) (Accessed August 27, 2020)
        • Knutson F.
        • Osselaer J.
        • Pierelli L.
        • et al.
        A prospective, active haemovigilance study with combined cohort analysis of 19,175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment.
        Vox Sang. 2015; 109: 343-352
        • Schulz W.L.
        • McPadden J.
        • Gehrie E.A.
        • et al.
        Blood utilization and transfusion reactions in pediatric patients transfused with conventional or pathogen reduced platelets.
        J Pediatr. 2019; 209: 220-225
        • Bhutani V.K.
        • Committee on Fetus and Newborn
        • American Academy of Pediatrics
        Phototherapy to prevent severe neonatal hyperbilirubinemia in the newborn infant 35 or more weeks of gestation.
        Pediatrics. 2011; 128: e1046-e1052
      4. “The right path to advancing blood safety: safe, simple, effective.” Mirasol® pathogen reduction technology.
        (Available at:) (Accessed August 31, 2020)
        • Terumo BCTbio
        Efficacy of mirasol-treated apheresis platelets in patients with hypoproliferative thrombocytopenia (MIPLATE). (Identifier: NCT02964325).
        (Available at:) (Accessed August 27, 2020)
        • Trakhtman P.
        • Karpova O.
        • Balashov D.
        • et al.
        Efficacy and safety of pathogen-reduced platelet concentrates in children with cancer: a retrospective cohort study.
        Transfusion. 2016; 56: S24-S28
        • Jimenez-Marco T.
        • Garcia-Recio M.
        • Girona-Llobera E.
        Use and safety of riboflavin and UV light-treated platelet transfusions in children over a five-year period: focusing on neonates.
        Transfusion. 2019; 59: 3580-3588
        • Franchini M.
        • Lippi G.
        Fibrinogen replacement therapy: a critical review of the literature.
        Blood Transfus. 2012; 10: 23-27
        • Costa-Filho R.
        • Hochleitner G.
        • Wendt M.
        • et al.
        Over 50 Years of fibrinogen concentrate.
        Clin Appl Thromb Hemost. 2016; 22: 109-114
      5. “FDA approves Fibryna”. US Food and Drug administration.
        (Available at:) (Accessed August 27, 2020)
        • Galas F.R.
        • de Almeida J.P.
        • Fukushima J.T.
        • et al.
        Hemostatic effects of fibrinogen concentrate compared with cryoprecipitate in children after cardiac surgery: a randomized pilot trial.
        J Thorac Cardiovasc Surg. 2014; 148: 1647-1655
        • Massoumi G.
        • Mardani D.
        • Mousavian S.M.
        • et al.
        Comparison of the effect of fibrinogen concentrate with fresh frozen plasma (FFP) in management of hypofibrinogenemic bleeding after congenital cardiac surgeries: a clinical trial study.
        ARYA Atheroscler. 2018; 14: 248-253
        • Salvin J.W.
        • Scheurer M.A.
        • Laussen P.C.
        • et al.
        Blood transfusion after pediatric cardiac surgery is associated with prolonged hospital stay.
        Ann Thorac Surg. 2011; 91: 204-210
        • Kipps A.K.
        • Wypij D.
        • Thiagarajan R.R.
        • et al.
        Blood transfusion is associated with prolonged duration of mechanical ventilation in infants undergoing reparative cardiac surgery.
        Pediatr Crit Care Med. 2011; 12: 52-56
        • Iyengar A.
        • Scipione C.N.
        • Sheth P.
        • et al.
        Association of complications with blood transfusions in pediatric cardiac surgery patients.
        Ann Thorac Surg. 2013; 96: 910-916
        • Wolf M.J.
        • Maher K.O.
        • Kanter K.R.
        • et al.
        Early postoperative bleeding is independently associated with increased surgical mortality in infants after cardiopulmonary bypass.
        J Thorac Cardiovasc Surg. 2014; 148: 631-636.e1
        • Downey L.A.
        • Andrews J.
        • Hedlin H.
        • et al.
        Fibrinogen concentrate as an alternative to cryoprecipitate in a postcardiopulmonary transfusion algorithm in infants undergoing cardiac surgery: a prospective randomized controlled trial.
        Anesth Analg. 2020; 130: 740-751
        • Giordano P.
        • Grassi M.
        • Saracco P.
        • et al.
        Human fibrinogen concentrate and fresh frozen plasma in the management of severe acquired hypofibrinogenemia in children with acute lymphoblastic leukemia: results of a retrospective survey.
        J Pediatr Hematol Oncol. 2019; 41: 275-279